Waters Corp
Company Profile
Business description
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Contact
34 Maple Street
MilfordMA01757
USAT: +1 508 478-2000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
7,600
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,304.47 | 192.08 | -0.75% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,802.77 | 55.36 | -1.43% |